BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

New Study Demonstrating Progenra, Inc.'s Novel Anti-Tumor Compound Overcome VELCADE® (bortezomib) Resistant Multiple Myeloma Cells


9/17/2012 9:34:11 AM

MALVERN, Pa.--(BUSINESS WIRE)--Researchers at the Dana-Farber Cancer Institute and Progenra, Inc. announce the publication of a research article entitled “A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance” (Chauhan et al, Cancer Cell). Data presented in this study include a comprehensive in vitro and in vivo analysis of the novel small molecule USP7 inhibitor P5091, discovered by Progenra. This selective inhibitor of USP7 induces anti-multiple myeloma activity alone and in combination with approved chemotherapeutic agents in cultured cells. Further, P5091 inhibits the growth of bortezomib resistant multiple myeloma tumor cells and suppresses tumor burden in distinct animal tumor models. In particular, when tested at their respective maximum tolerated doses, P5091 and VELCADE® repressed myeloma xenograft growth with equivalent efficacies. The lead author of the study Dr. Dharminder Chauhan stated, “Targeting the ubiquitin proteasome system upstream of the proteasome, as exemplified by these studies with Progenra’s USP7 inhibitor P5091, offers a novel opportunity for new treatments for multiple myeloma and other refractory cancers.”

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES